Literature DB >> 12908725

Malaria in Turkey: a review of 33 cases.

A Mert1, R Ozaras, F Tabak, M Bilir, R Ozturk, Y Aktuglu.   

Abstract

AIM: To evaluate epidemiologic and clinical features of the patients with malaria followed in our clinic, and to review current status of malaria in our country. PATIENTS AND METHODS: Epidemiologic, clinical, diagnostic, and therapeutic features of 33 patients with malaria (4 female, 29 male, mean age: 28 +/- 11 years, range: 15-60) followed in our clinic between 1981 and 2000 were evaluated retrospectively. Malaria data of our country for 1926-2000 were obtained from Health Ministry.
RESULTS: Diagnosis was established by thin smears of blood preparations obtained in the febrile period in all cases. Plasmodium vivax was detected in 26 patients (25 domestic and one imported), and P. falciparum in seven (two domestic and five imported). Sixty-one percent of the patients had the prodromal symptoms of the disease and used various antibiotics. All cases demonstrated the typical pattern of fever with chills. Fever (100%), splenomegaly (91%), hepatomegaly (55%), anemia (70%), leukopenia (48%), thrombocytopenia (48%), a rise in sedimentation rate (100%), and abnormalities in hepatic enzymes (30%) were determined in the patients. Chloroquine + primaquine were given to all patients with P. vivax, chloroquin (for three) or mefloquin (for four) alone were given to the patients with P. falciparum. One patient with P. falciparum died soon after admission, all the remaining recovered. Data from Health Ministry revealed that the most common (approximately 100%) species in our country is P. vivax. Although an eradication program against malaria initiated in 1926 achieved success, it still remains as an important health problem.
CONCLUSION: Every febrile patient with a history of travel to the regions where malaria is endemic (tropical regions for the world, southeast regions for our country) should raise the suspicion of malaria. Every country should fight against malaria and global cooperation is essential.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12908725     DOI: 10.1023/a:1024648902848

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  7 in total

1.  Acute surgical abdomen: an atypical presentation of Plasmodium vivax malaria.

Authors:  Sunil Gopisetty; Jonahan Sarveswaran; Raj Achuthan; J Davies; J R Ausobsky
Journal:  Gut       Date:  2007-03       Impact factor: 23.059

2.  Monitoring of failure of chloroquine treatment for Plasmodium vivax using polymerase chain reaction in Sanliurfa province, Turkey.

Authors:  Fuat Dilmec; M Ali Kurcer; Feridun Akkafa; Zeynep Simsek
Journal:  Parasitol Res       Date:  2010-02-06       Impact factor: 2.289

3.  Clinical features and haematological parameters among malaria patients in Mangaluru city area in the southwestern coastal region of India.

Authors:  Kishore Punnath; Kiran K Dayanand; Valleesha N Chandrashekar; Rajeshwara N Achur; Srinivas B Kakkilaya; Susanta K Ghosh; Benudhar Mukhi; Vishal Midya; Suchetha N Kumari; D Channe Gowda
Journal:  Parasitol Res       Date:  2019-11-21       Impact factor: 2.289

4.  Real-time PCR for dihydrofolate reductase gene single-nucleotide polymorphisms in Plasmodium vivax isolates.

Authors:  Sara Brega; Frédérique de Monbrison; Carlo Severini; Rachanee Udomsangpetch; Inge Sutanto; Paul Ruckert; François Peyron; Stéphane Picot
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

5.  Theoretical investigation of malaria prevalence in two Indian cities using the response surface method.

Authors:  Sayantani Basu Roy; Ram Rup Sarkar; Somdatta Sinha
Journal:  Malar J       Date:  2011-10-14       Impact factor: 2.979

6.  Thrombocytopenia as an indicator of malaria in adult population.

Authors:  Shiraz Jamal Khan; Yasir Abbass; Mumtaz Ali Marwat
Journal:  Malar Res Treat       Date:  2012-07-02

7.  Etiological causes of pancytopenia: A report of 137 cases.

Authors:  Osman Yokuş; Habip Gedik
Journal:  Avicenna J Med       Date:  2016 Oct-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.